Transgene Biotek Limited reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2020. For the quarter, on a standalone basis, the company reported total income of INR 438,470 compared to INR 509,164 a year ago. Loss for the year was INR 26,734,835 compared to INR 27,326,303 a year ago. Basic and diluted loss per share was INR 0.35 compared to INR 0.36 a year ago. For the six months, on a standalone basis, the company reported total income of INR 876,940 compared to INR 947,634 a year ago. Loss for the year was INR 53,103,899 compared to INR 55,139,397 a year ago. Basic and diluted loss per share was INR 0.70 compared to INR 0.73 a year ago. For the quarter, on a consolidated basis, the company reported total income of INR 438,470 compared to INR 509,164 a year ago. Loss for the year was INR 26,734,835 compared to INR 27,326,303 a year ago. Basic and diluted loss per share was INR 0.35 compared to INR 0.36 a year ago. For the six months, on a consolidated basis, the company reported total income of INR 876,940 compared to INR 947,634 a year ago. Loss for the year was INR 53,103,899 compared to INR 55,139,397 a year ago. Basic and diluted loss per share was INR 0.73 compared to INR 1.45 a year ago.